Baudax Bio, Inc.

BXRXQOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$4359

P/E Ratio—

52W High$0.0001

52W Low$0.00001

Avg Volume3K

Open$0.00

Beta-11.87

Earnings Financials Revenue

Baudax Bio, Inc. (BXRXQ) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

BXRXQ · earnings · updated Jun 8, 2026

Latest Earnings

Q3 FY2023Report Date: Aug 16, 2023

EPS Actual

-$1.49

Est. -$2.04 · +27.0%

Revenue

—

Fiscal Period

Q3 FY2023

FY ends December

Report Date

Aug 16, 2023

After Market Close

▲ Beat EPS✓ 1-Quarter EPS Beat Streak

BXRXQ reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.21

Rev. $0.66B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.21

Rev. Est.$0.66B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 19, 2026	-$280.00	—	—	—	$0.00B	—
◌ Q2 FY2026	May 29, 2026	—	—	—	—	—	—
◌ Q2 FY2026	May 15, 2026	-$280.00	—	—	—	$0.00B	—
◌ Q1 FY2026	Feb 26, 2026	-$270.67	—	—	—	$0.00B	—
◌ Q1 FY2025	Feb 11, 2025	—	—	—	—	—	—
◌ Q4 FY2024	Nov 15, 2024	—	—	—	—	—	—
◌ Q3 FY2024	Aug 16, 2024	-$0.09	—	—	—	—	—
◌ Q2 FY2024	May 16, 2024	-$0.12	—	—	—	—	—

Q3 FY2026

Aug 19, 2026

EPS Actual

—

EPS Est.

-$280.00

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 29, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 15, 2026

EPS Actual

—

EPS Est.

-$280.00

EPS Surpr.

—

Revenue

—

Q1 FY2026

Feb 26, 2026

EPS Actual

—

EPS Est.

-$270.67

EPS Surpr.

—

Revenue

—

Q1 FY2025

Feb 11, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2024

Nov 15, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2024

Aug 16, 2024

EPS Actual

—

EPS Est.

-$0.09

EPS Surpr.

—

Revenue

—

Q2 FY2024

May 16, 2024

EPS Actual

—

EPS Est.

-$0.12

EPS Surpr.

—

Revenue

—

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q3 FY2030	$-0.08	$-0.08	$-0.08	1
Q2 FY2030	$-0.09	$-0.09	$-0.09	1
Q1 FY2030	$-0.09	$-0.09	$-0.09	1
Q4 FY2029	$-0.08	$-0.08	$-0.08	1
Q3 FY2029	$-0.09	$-0.09	$-0.09	1
Q2 FY2029	$-0.09	$-0.09	$-0.09	1

Revenue Estimates

Period	Low	Consensus	High
Q3 FY2030	$0.0B	$0.0B	$0.0B
Q2 FY2030	$0.0B	$0.0B	$0.0B
Q1 FY2030	$0.0B	$0.0B	$0.0B
Q4 FY2029	$0.0B	$0.0B	$0.0B
Q3 FY2029	$0.0B	$0.0B	$0.0B
Q2 FY2029	$0.0B	$0.0B	$0.0B

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q3 FY2023	Aug 16, 2023	+27.0%	No price data	—	—
▼ Q2 FY2023	May 12, 2023	-14.6%	No price data	—	—

Q3 FY2023—

Report Date

Aug 16, 2023

EPS Beat/Miss

+27.0%

Price Before

—

Price After

—

Q2 FY2023—

Report Date

May 12, 2023

EPS Beat/Miss

-14.6%

Price Before

—

Price After

—

Beat Rate1 / 2 quarters

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Baudax Bio, Inc. (BXRXQ) most recently reported earnings on August 16, 2023 for Q3 FY2023, posting EPS of $-1.49 — beating the analyst consensus of $-2.04 by +27.0%. The next BXRXQ earnings date is expected around September 1, 2026.

Each quarter, investors track BXRXQ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BXRXQ revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

BXRXQ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

BXRXQ earnings · 4 questions

Baudax Bio, Inc.'s next earnings report is expected around September 1, 2026. BXRXQ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BXRXQ historically reports after market close (AMC).

BXRXQ earnings datewhen is BXRXQ earningsBXRXQ next earnings datewhen does BXRXQ report earningsBXRXQ earnings calendar

▸ Source: FMP · Baudax Bio, Inc. SEC filings · US GAAP · Baudax Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026